Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Showcase Companies

Stockhouse is proud to showcase a portfolio of companies that we are watching closely. Learn more about these companies as part of your own investment research. Consider using the tools below to be first in line for important news and updates. view all showcase companies

NurExone Biologic Inc. V.NRX

NurExone Biologic Inc. is a pharmaceutical company. The Company is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and proprietary sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a proprietary platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

Latest News

NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization


NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and...


NurExone Biologic Secures Master Cell Bank


A potential breakthrough in spinal cord and optic nerve injury treatment


NurExone Biologic announces important test results


NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage


NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update


NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating...


NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate...


NurExone's Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA


NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M


NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences


NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in...


NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update


NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September...